Unicycive Therapeutics Appointed Meredith Manning to Board
The biotech firm added the executive to support its transition into a commercial-stage company.
Updated on Oct. 1, 2026 in People
Unicycive Therapeutics has appointed Meredith Manning to its Board of Directors to help guide the company's strategic goals. Manning joins the Mountain View-based firm as it advances toward its target of bringing oxylanthanum carbonate to patients.
Why it matters
The appointment bolsters the company leadership as it prepares to transition from a clinical-stage entity to a commercial-stage organization. Manning brings 25 years of global biopharmaceutical experience to the board.
Meredith Manning brings 25 years of biopharmaceutical experience to her new role on the board. She will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees.
The players
Meredith Manning
She is a biopharmaceutical executive who holds an M.B.A. and has served in leadership roles at Soleno Therapeutics and PharmaEssentia Corporation.
Unicycive Therapeutics
Based in Mountain View, this clinical-stage biotechnology company focuses on the development of novel therapies for kidney disease.
The details
Manning will serve as Chairperson of the Nominating and Corporate Governance Committee to support the biotechnology company's overarching strategy. She previously served as Chief Commercial Officer of Soleno Therapeutics from 2024 to 2026 and as an executive at PharmaEssentia Corporation from 2020 to 2023.
Timeline
Meredith Manning served as an executive at PharmaEssentia Corporation from 2020 to 2023.
Manning served as the Chief Commercial Officer of Soleno Therapeutics from 2024 to 2026.
Unicycive Therapeutics appointed Meredith Manning to its board on October 1, 2026.
Market Landscape
This strategic appointment reflects the broader industry trend of clinical-stage firms shifting their leadership focus toward commercialization expertise as they approach product launches. The move positions Unicycive Therapeutics to navigate the competitive kidney disease therapy market more effectively.
The transition to a commercial-stage company may eventually lead to greater availability of kidney disease therapies for patients. While the board appointment does not impact immediate pricing, it marks a significant milestone in the company roadmap toward product commercialization.
The takeaway
Bringing in experienced leadership is a key indicator that a biotechnology company is moving toward market readiness. Investors and patients should monitor the firm's progress in securing regulatory approval for its primary therapy, oxylanthanum carbonate.
Further reading
For more on industry leadership changes, visit People.
